• Transparancy of qualtity of care goes beyond mortality rates

    Zorgvisie – December 3rd, 2012

    In December 2012 a number of hospitals made their mortality rate or so called HSMR (Hospital Standarised Mortality Ratio) public. This is an important step towards transparency of quality of care delivery.  However, we cannot rely on HSMR warns Piet-Hein Buiting the new CEO of Santeon (joint force of six top clinical Dutch hospitals). Comparing hospitals based on HSMR is unreliable and the number tells us nothing about the performance of individual departments. If we really want to give insight in quality of care, we need more specific data. In this respect Piet-Hein Buiting praises Meetbaar Beter, the joint effort of  the heart centres of Catharina  Hospital, St. Antonius Hospital Nieuwegein and The Decision Group.

    Outcome Measures

    With the Value Based Healthcare Center Europe, The Decision Group strives to develop patient relevant medical outcome measures that facilitate decision making and dialogue, making quality comprehensible. We provide clear insight in the whole cycle of care around a medical condition. Together with medical specialists, professionals and patients, the outcomes that are most relevant for the patient are successfully determined. Our methodology was successfully implemented in the project Meetbaar Beter.

    If you are interested to learn more about Value Based Healthcare and the use of Outcome Measures, please refer to our Clinical Management Workshop Series and our specialized Masterclasses Value Based Health Care.

    Visit our Value Based Health Care Center and learn, share and inspire!

    Continue reading
  • Understand your customers – Innovation & Growth

    “Understand your customers, your own DNA and design your own business model! But formost, timing. Timing of strategic moves is crucial.” These were the two main conclusions of case teacher and innovation expert Ir. Maarten Koomans during the workshop Innovation & Growth of the Strategy & Governance Excellence Series of affiliate The Decision Institute.

    Apple Inc as best practice

    Take Apple. It has been a rocky-ride for most of their existence. Sure, now they are the most valueable company with a P/E of 13, but not always. What connects their NOW with their PAST is the profile of their customer base, innovation capabilities combined with their own true understanding of design and users. The Intel move should not have happened two years earlier or later. Both would have been disasterous. The Business Model Canvas serves in this discussion as a super conversation tool to understand where your core is, and where you might look to find a starting point for new approaches/products/services.

    Continuously, business environments change; new competitors enter the market, new technologies appear and other substitution services or products reach your clients. To stay ahead of the curve, it is necessary to think about your business model over and over again.

    • What is the added value for the client?
    • What are the key activities of the business?
    • What are the costdrivers of the business?

    Partnering with Business Models Inc., The Decision Group can visualize and develop a value proposition for your business, with the tool: Advanced Business Model Canvas.

    More Information

    For more information about the Strategy & Governance Excellence Series of affiliate The Decision Institute, can be found on our website.

    Continue reading
  • Clinical Management Workshop Series

    The Decision Group organizes with The Decision Institute a series of Clinical Management workshops on the latest academic insights.
    Please click here for the brochure, or go to the dedicated website on the workshop series.

    Continue reading
  • The Decision Group starts development of Prosensa Case

    Case on the succes of a Dutch biotech company

    The Decision Group has initiated a research project on the Dutch biotech company Prosensa (www.prosensa.nl) and conducts the research with a consortium of partners.
    The research was initiated because of an international academic need for a Harvard style case on relevant and recent strategic topics that biotech companies face. In addition there is a need in The Netherlands to show a success story within the cluster, while Dutch pharma and biotech are facing tough times. Important aspects are the Public-private partnerships, academic institutions and increased focus on the valorization of knowledge.


    The objective of the case is to demonstrate, with a thorough and academic Harvard style case, a success story of the Dutch biotech cluster which can be used for (international) teaching at various universities and for promotional activities within the Netherlands or abroad.

    Continue reading